Altimmune Sets H2 2026 for Pivotal Phase III MASH Trial Initiation
ALT sits 18% above its 52-week low of $2.56.
Summary
Altimmune announced plans to initiate its pivotal Phase III MASH trial for pemvidutide in the second half of 2026, a significant advancement for its lead drug candidate. The company also reported a Q1 net loss of $22.6 million and a strong cash position of $535 million following a recent public offering. While the Q1 financial results were largely covered by an earlier 8-K filing, the specific timeline for the Phase III trial initiation is new and highly material. Advancing to Phase III is a critical de-risking event and a major catalyst for Altimmune, a clinical-stage biotech, signaling substantial progress towards potential commercialization in the large MASH market. Traders will now closely monitor the exact timing of the trial's commencement and subsequent enrollment updates.
At the time of this announcement, ALT was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587M. The 52-week trading range was $2.56 to $7.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.